Movement Disorders

As part of NeurologyLive®'s Year in Review, we've compiled the most-read question-and-answer interviews we've conducted with experts in various neurology specialties in 2022.

Using focused ultrasound waves, the Exablate Neuro platform has now gained the FDA greenlight for medication-refractory essential tremor, tremor-dominant Parkinson disease, and second side of essential tremor.

The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 16, 2022.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and related dementias.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 9, 2022.

Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

The president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 25, 2022.

The president of the International Neuropalliative Care Society provided perspective on the growth of the field of neuropalliative care, the organization’s role, and how clinicians are overcoming current barriers in place.

The president of the International Neuropalliative Care Society discussed the area in which neuropalliative has expanded and improved, as well as the potential in the coming years. [WATCH TIME: 2 minutes]

The president of the International Neuropalliative Care Society provided an overview of the organization’s recently concluded conference and the significance of the growth of neuropalliative care. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Over a 12-week treatment period, treatment with continuous subcutaneous carbidopa/levodopa resulted in significantly greater increase in ON time and reduced OFF time, while demonstrating a safe profile.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.